Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia


REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.

The purpose of this study is to evaluate the effect of a range of interventions to improve outcome ofon patients admitted to intensive care with community-acquired pneumonia.

In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness.

REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.


Charité – Universitätsmedizin Berlin – Infektiologie und Pneumologie: Prof. Dr. Martin Witzenrath

Charité – Universitätsmedizin Berlin – Nephrologie: Dr. André Finn

Vivantes Klinikum Neukölln, Berlin: Dr. Lorenz Reill

Universitätsklinikum Köln: Lars Pester

Universitätsklinikum Frankfurt: Prof. Dr. Gernot Rohde

Universitätsklinikum Hamburg-Eppendorf: Prof. Dr. Stefan Klug

Medizinische Hochschule Hannover: Dr. Sascha David

Universitätsklinikum Jena: Prof. Dr. Mathias W. Pletz, Email: mathias.pletz@med.uni-jena.de

Universitätsklinikum Leipzig: Prof. Dr. Sirak Petros, Email: Sirak.Petros@uniklinik-leipzig.de

Universitätsklinikum Tübingen: Dr. Siri Göpel

Universitätsklinikum Würzburg: Dr. Dirk Weismann

REMAP-CAP Study Website




Stand: 05.05.2020, Quelle: www.clinicaltrials.gov